Nature Reviews Rheumatology

Article	Citations
Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors	566
Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes	402
Translating IL-6 biology into effective treatments	361
Mechanisms and therapeutic implications of cellular senescence in osteoarthritis	283
Autoimmune and inflammatory diseases following COVID-19	281
Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment	276
Synovial inflammation in osteoarthritis progression	248
Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines	232
Global epidemiology of systemic lupus erythematosus	228
Emerging pharmaceutical therapies for osteoarthritis	206
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	189
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications	187
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	183
Systemic and organ-specific immune-related manifestations of COVID-19	182
IgG4-related disease: an update on pathophysiology and implications for clinical care	164
The gut–joint axis in rheumatoid arthritis	161
New insights into the role of antinuclear antibodies in systemic lupus erythematosus	141
Kawasaki disease: pathophysiology and insights from mouse models	141
Toll-like receptor signalling in B cells during systemic lupus erythematosus	140
COVID-19 revisiting inflammatory pathways of arthritis	138
Early-stage symptomatic osteoarthritis of the knee — time for action	135
A new immunometabolic perspective of intervertebral disc degeneration	133
Ankylosing spondylitis: an autoimmune or autoinflammatory disease?	131
Immune-mediated necrotizing myopathy: clinical features and pathogenesis	128
Cell-based strategies for IVD repair: clinical progress and translational obstacles	125

Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison	124
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	124
Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis	121
Mechanosignalling in cartilage: an emerging target for the treatment of osteoarthritis	118
Global epidemiology of vasculitis	118
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis	115
Combating physical inactivity during the COVID-19 pandemic	113
Rheumatic disease and COVID-19: epidemiology and outcomes	112
Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	105
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	105
Digital health technologies: opportunities and challenges in rheumatology	104
The non-coding RNA interactome in joint health and disease	103
Epithelial–immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis	102
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	101
Oral surveillance and JAK inhibitor safety: the theory of relativity	91
Interplay between genetics and epigenetics in osteoarthritis	90
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases	85
PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets	81
Fibroblast growth factor signalling in osteoarthritis and cartilage repair	78
TNF in the era of immune checkpoint inhibitors: friend or foe?	76
Cell death in chronic inflammation: breaking the cycle to treat rheumatic disease	75
Immune cartography of macrophage activation syndrome in the COVID-19 era	74
Axial spondyloarthritis: concept, construct, classification and implications for therapy	74
The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic	73
The endothelium–bone axis in development, homeostasis and bone and joint disease	70
The evolution of nerve growth factor inhibition in clinical medicine	69
Location, location, location: how the tissue microenvironment affects inflammation in RA	65
Sex steroids and autoimmune rheumatic diseases: state of the art	65
Current and future therapies for primary Sjögren syndrome	64
Interleukin-2 and regulatory T cells in rheumatic diseases	59
Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research	57
Targeting interferon-γ in hyperinflammation: opportunities and challenges	56
Treat-to-target in systemic lupus erythematosus: advancing towards its implementation	56
Treatment of axial spondyloarthritis: an update	56
Global epidemiology of rheumatoid arthritis	55
Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica	55
Cardiovascular effects of approved drugs for rheumatoid arthritis	55
Transforming clinical trials in rheumatology: towards patient-centric precision medicine	54
Insights into the biology and therapeutic implications of TNF and regulatory T cells	53
Biological classification of childhood arthritis: roadmap to a molecular nomenclature	52
Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission	52
Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential	51
Lyme arthritis: linking infection, inflammation and autoimmunity	50
MIS-C: early lessons from immune profiling	50
Psoriatic arthritis from a mechanistic perspective	49
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	49
The decisive early phase of bone regeneration	49
Why remission is not enough: underlying disease mechanisms in RA that prevent cure	49
Clinical value of DNA methylation markers in autoimmune rheumatic diseases	48
Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care	45

The role of HIF proteins in maintaining the metabolic health of the intervertebral disc	43
Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases	42
Detection of microvascular changes in systemic sclerosis and other rheumatic diseases	42
Immunogenicity of biologic agents in rheumatology	42
Erosive hand osteoarthritis: latest findings and outlook	41
Interferon lambda in inflammation and autoimmune rheumatic diseases	40
Core and adjunctive interventions for osteoarthritis: efficacy and models for implementation	38
Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases	38
Disorders of ubiquitylation: unchained inflammation	38
Hypertension meets osteoarthritis — revisiting the vascular aetiology hypothesis	37
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities	37
An introduction to machine learning and analysis of its use in rheumatic diseases	35
Key opinion leaders — a critical perspective	35
Inflammation and DNA damage: cause, effect or both	34
Applying precision medicine to unmet clinical needs in psoriatic disease	34
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	34
From risk to chronicity: evolution of autoreactive B cell and antibody responses in rheumatoid arthritis	34
Biomarker development for axial spondyloarthritis	33
The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	33
Mechanisms and clinical implications of intervertebral disc calcification	32
Vascular Behçet syndrome: from pathogenesis to treatment	32
The role of neutrophils in rheumatic disease-associated vascular inflammation	32
Rheumatic diseases in Africa	31
Sex- and gender-related differences in psoriatic arthritis	30
Cartilage calcification in osteoarthritis: mechanisms and clinical relevance	30
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	29
Importance of lymphocyte–stromal cell interactions in autoimmune and inflammatory rheumatic diseases	27
Acute exacerbation of interstitial lung disease associated with rheumatic disease	27
Failure of cartilage regeneration: emerging hypotheses and related therapeutic strategies	26
How COVID-19 is changing rheumatology clinical practice	25
Immunological memory in rheumatic inflammation — a roadblock to tolerance induction	25
Joint-on-chip platforms: entering a new era of in vitro models for arthritis	25
Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management	24
Studying osteoarthritis with artificial intelligence applied to magnetic resonance imaging	24
Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases	24
Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study	24
The role of mitochondria in rheumatic diseases	24
Effects of targeted therapies on bone in rheumatic and musculoskeletal diseases	24
Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia	24
Treat-to-target in axial spondyloarthritis — what about physical function and activity?	22
Adopting PROs in virtual and outpatient management of RA	22
High risk of autoimmune diseases after COVID-19	22
Disease stratification in GCA and PMR: state of the art and future perspectives	22
State-of-the-art evidence in the treatment of systemic sclerosis	22
Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum	22
Matrix metalloproteinases in arthritis: towards precision medicine	22
Differentiating between UCTD and early-stage SLE: from definitions to clinical approach	21
Regulation of activated T cell survival in rheumatic autoimmune diseases	21
Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies	21
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	20
Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis	20
Challenges in the management of older patients with inflammatory rheumatic diseases	20
Emerging concepts of type I interferons in SLE pathogenesis and therapy	20
Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis	19
Glycobiology of rheumatic diseases	19
Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease	18
Endothelial function and endothelial progenitor cells in systemic lupus erythematosus	18
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	18
Treatment of lupus nephritis: consensus, evidence and perspectives	17
Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need	17
Machine learning in precision medicine: lessons to learn	16
Precision medicine in systemic lupus erythematosus	15
Precision medicine: the precision gap in rheumatic disease	15
Targeting calcium-related mechanotransduction in early OA	15
New insights into the treatment of CTD-ILD	13
Diagnostic role of anti-dsDNA antibodies: do not forget autoimmune hepatitis	13
Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management	12
Busting the myth of methotrexate chronic hepatotoxicity	12
Involvement of the secosteroid vitamin D in autoimmune rheumatic diseases and COVID-19	12
JAK inhibitors and VTE risk: how concerned should we be?	12
Mapping the musculoskeletal system one cell at a time	11
Age-related mechanisms in the context of rheumatic disease	10
Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care	10
Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone	10
When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy	10
Assessment of disease outcome measures in systemic sclerosis	10
TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond	10
Genome editing to define the function of risk loci and variants in rheumatic disease	10
Evolving concepts in systemic lupus erythematosus damage assessment	10
Revisiting the cardiovascular risk of hydroxychloroquine in RA	9

Striking a balance in rheumatoid arthritis prevention trials	8
New insights into RA genetics from GWAS meta-analysis	8
The road to equity for women in academic rheumatology	8
Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies	8
Spectrum and impact of checkpoint inhibitor-induced irAEs	8
Hydroxychloroquine dose: balancing toxicity and SLE flare risk	7
The bone marrow side of axial spondyloarthritis	7
Critical appraisal of serum urate targets in the management of gout	7
Skin–kidney crosstalk in SLE	7
The Musculoskeletal Knowledge Portal: improving access to multi-omics data	7
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	7
Does psoriasis treatment affect PsA development?	7
The (Orf)ull truth about IRF5 and type I interferons in SLE	6
Osteocyte death promotes bone loss	6
NETs directly injure cartilage in RA	6
Linking cell mechanobiology and inflammation in IVD degeneration	6
Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021	6
Synovial macrophage populations linked to RA remission	6
Kawasaki disease and MIS-C share a host immune response	6
HIPPOCRATES: improving diagnosis and outcomes in psoriatic arthritis	6
Somatic mutations cause VEXAS syndrome	6
Innate immune memory in inflammatory arthritis	5
Publisher Correction: Global epidemiology of systemic lupus erythematosus	5
2021 ACR guideline reflects changes in RA treatment	5
Targeted delivery of immunosuppressant in SLE	5
Targeting FLS signalling in RA	5
New refinements aim to optimize articular cartilage tissue engineering	5
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	5
Linking NAD metabolism and DNA repair to inflammation in SSc	5
TNF inhibition for immune checkpoint inhibitor-induced irAEs: the jury is still out	5
JAK inhibitors: new indication and emerging safety data in 2022	5
PDGF-BB is the key to unlocking pathological angiogenesis in OA	5
Voclosporin improves outcomes in lupus nephritis	5
Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells	5
IL-17A and IL-17F in tissue homeostasis, inflammation and regeneration	5
Effect of DMARDs on the immunogenicity of vaccines	4
Telemedicine: a solution for everyone?	4
COVID-19 vaccination in individuals with inflammatory rheumatic diseases	4
SUMOylation links metabolic and aggressive phenotype of RA FLS	4
Progress continues in prediction of the response to treatment of RA	4
Disease onset goes with its gut in RA	4
IL-17 sustains plasma cells in SLE	4
A path towards personalized medicine for autoinflammatory and related diseases	4
Epidemiology of Sjögren syndrome	4
Exercise exerts anti-inflammatory effects on muscle via the JAK–STAT pathway	4
Synovial fibroblast expansion in RA is driven by Notch signalling	4
How does age determine the development of human immune-mediated arthritis?	4
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	4
Combination therapy for septic arthritis	4
A comprehensive guide for managing the reproductive health of patients with vasculitis	4
MIS-C: myths have been debunked, but mysteries remain	4
IL-33 is a potential new target in OA	4
Removing barriers and disparities in health: lessons from the COVID-19 pandemic	4
Cross-trial comparisons in reviews: proceed with caution	4
How do dietary interventions affect serum urate and gout?	3
Genetic risk scores in inflammatory arthritis: a new era?	3
Immune mechanisms of depression in rheumatoid arthritis	3
Cardio-rheumatology: it’s time to collaborate	3
Opioid and Hedgehog signalling pathways converge to modulate OA	3
Epidemiology of the idiopathic inflammatory myopathies	3
Optimizing methotrexate withdrawal during COVID vaccination	3
What could a new disease activity score for polymyalgia rheumatica do better?	3
Different phenotypes identified for Behçet syndrome	3
Imaging in inflammatory arthritis: progress towards precision medicine	3
How well do the new classification criteria for SLE perform?	3
Beyond joint pain, could each gout flare lead to heart attack?	3
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	3
Pain in OA: is cartilage loss a major contributor?	3
Mechanisms and rationale for uricase use in patients with gout	3
Down syndrome: insights into autoimmune mechanisms	3
In silico tools predict effects of drugs on bone remodelling	3
Post-transcriptional checkpoints in autoimmunity	3
NETs revealed as source of carbamylated proteins in RA	3
GCA management guidelines — vive la différence?	3
Switching on resolution to treat RA moves closer to reality	3
New data emerging on outcomes for patients with COVID-19 and rheumatic diseases	3
Pathogenic role for MIF likely in SpA	3
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	3
Back to the future: targeting the extracellular matrix to treat systemic sclerosis	3
Complement therapeutics are coming of age in rheumatology	3
Keeping immunostimulatory self-RNA under the rADAR	3
Ageing stem cells hold the key to age-related bone degeneration	3
Safety and efficacy of HSCT for systemic sclerosis across clinical trials	3
Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce	3
Targeting senescence in OA	3
Synthetic Wnt agonists rapidly rebuild bone in vivo	3
Publisher Correction: Revisiting the gut–joint axis: links between gut inflammation and spondyloarthritis	3
Gut microbiome could predict drug response in RA	3
Targeting the CCR6–CCL20 axis improves experimental PsA	3
Discontinuing methotrexate to enhance vaccine response	2
Anti-inflammatory TNF receptor 2 signalling unravelled	2
Targeting articular Mmp13 in OA	2
CAR T cells induce remission in a patient with refractory SLE	2
Learning from similarities between vaccine responses and SLE	2
Kindlin-2 reduces IVD inflammation	2